Nikolai A. Lisitsyn

Dr. Nikolai A. Lisitsyn


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Biochimie
Verified
Journal Article
Closed access
OZOlga L. Zinovieva
Olga L. Zinovieva
EGEvgenia N. Grineva
Evgenia N. Grineva
MPMaria M. Prokofjeva
Maria M. Prokofjeva
Dmitry KarpovDmitry Karpov
Dmitry Karpov
AZAndrei O. Zheltukhin
Andrei O. Zheltukhin
NLNikolai A. Lisitsyn
Nikolai A. Lisitsyn

1 January 2019 in Journal of Cancer
Verified
Journal Article
Open access
OZOlga L. Zinovieva
Olga L. Zinovieva
EGEvgeniya N. Grineva
Evgeniya N. Grineva
GKGeorge S. Krasnov
George S. Krasnov
Dmitry KarpovDmitry Karpov
Dmitry Karpov
AZAndrei O. Zheltukhin
Andrei O. Zheltukhin
NLNikolai A. Lisitsyn
Nikolai A. Lisitsyn
Using RNA-seq, RT-qPCR, and bioinformatics we have studied the influence of a wide spectrum of chemotherapeutic drugs on transcription of AKRIBIO, AKRICI, ALDHIAI, and ALDHIA3 genes, which encode the major aldehyde-metabolizing enzymes. The strongest alterations were detected in case of AKRIBIO mRNA that was significantly upregulated in wild type p53 cancer cells, but downregulated in mutant p53 cancer cells. Subsequent experiments demonstrated the significant and consistent decrease in the AKRIBIO mRNA content in sera of colon cancer patients, as compared to sera of healthy donors (p<0.0001, SPE=92.9%, SNE=79.3%, AUC=0.889), which implies that this RNA is a valuable marker for serological diagnosis of colorectal cancer. Moreover, we have found that ALDHIA3 protein is a key inactivator of ROS-generated aldehydes, which is a perspective target for the development of new chemotherapeutic drugs.

Verified
Journal Article
Open access
PDF file
Dmitry KarpovDmitry Karpov
Dmitry Karpov
PSPavel Spirin
Pavel Spirin
AZAndrey O. Zheltukhin
Andrey O. Zheltukhin
VTVera V. Tutyaeva
Vera V. Tutyaeva
OZOlga L. Zinovieva
Olga L. Zinovieva
NLNikolai A. Lisitsyn
Nikolai A. Lisitsyn
Overcoming drug resistance of cancer cells is the major challenge in molecular oncology. Here, we demonstrate that long non-coding RNA LINC00973 is up-regulated in normal and cancer cells of different origins upon treatment with different chemotherapeutics. Bioinformatics analysis shows that this is a consequence of DNA damage response pathway activation or mitotic arrest. Knockdown of LINC0973 decreases p21 levels, activates cellular proliferation of cancer cells, and suppresses apoptosis of drug-treated cells. We have found that LINC00973 strongly increases p21 protein content, possibly by blocking its degradation. Besides, we have found that ectopic over-expression of LINC00973 inhibits formation of the pro-survival p53-Ser15-P isoform, which preserves chromosome integrity. These results might open a new approach to the development of more efficient anti-cancer drugs.

1 September 2017 in Molecular Biology
Verified
Journal Article
Closed access
PDF file
OZO. L. Zinovieva
O. L. Zinovieva
EGE. N. Grineva
E. N. Grineva
MPM. M. Prokofjeva
M. M. Prokofjeva
Dmitry KarpovDmitry Karpov
Dmitry Karpov
GKG. S. Krasnov
G. S. Krasnov
NLNikolai A. Lisitsyn
Nikolai A. Lisitsyn
Using real-time RT-PCR in combination with bioinformatics, we have shown for the first time that the treatment of HCT-116 and HT-29 colon cancer cells with two anti-cancer agents (doxycycline or 3,3′-diindolylmethane) results in profound changes in the intracellular content of several lncRNAs (by up to 100 times). Since many of these RNAs are secreted by tumors into the bloodstream, the obtained results provide a basis for developing more sensitive protocols for serological monitoring of tumor relapse and metastasis, as well as for search of new anti-cancer drugs.